Investment Thesis
Despite strong 11.5% revenue growth, Medline's profitability is deteriorating with net income declining YoY and a critically thin net margin of 1.8%. The company's exceptionally poor returns (1.2% ROE, 0.3% ROA) combined with elevated leverage ($12.5B debt on $11.3B equity) indicate fundamental operational challenges that are eroding shareholder value even as top-line expands.
Strengths
- Strong revenue growth of 11.5% YoY demonstrates market demand in medical instruments sector
- Excellent liquidity position with 4.41x current ratio and 2.51x quick ratio providing financial flexibility
- Positive free cash flow of $316M (4.3% FCF margin) shows cash generation capability despite thin net margins
Risks
- Net income declined 0.9% YoY despite 11.5% revenue growth, signaling severe margin compression and operational distress
- Critically low net margin of 1.8% and net profit of only $132M on $7.4B revenue indicates pricing pressure or cost control issues
- Elevated debt-to-equity ratio of 1.11x ($12.5B debt) combined with minimal profitability creates refinancing and solvency risk
- Abysmal returns on equity (1.2%) and assets (0.3%) demonstrate inefficient capital deployment destroying shareholder value
Key Metrics to Watch
- Operating margin trend - critical to determine if 5.7% can stabilize or will compress further
- Net income trajectory - must return to growth to justify debt burden and asset base
- Debt service coverage ratio - essential given high leverage and thin profitability
- Return on equity progression - needs substantial improvement toward 10%+ to justify equity investment
Financial Metrics
Revenue
7.4B
Net Income
132.0M
EPS (Diluted)
$0.16
Free Cash Flow
316.0M
Total Assets
39.0B
Cash
2.2B
Profitability Ratios
Gross Margin
25.0%
Operating Margin
5.7%
Net Margin
1.8%
ROE
1.2%
ROA
0.3%
FCF Margin
4.3%
Balance Sheet & Liquidity
Current Ratio
4.41x
Quick Ratio
2.51x
Debt/Equity
1.11x
Debt/Assets
50.4%
Interest Coverage
N/A
Long-term Debt
12.5B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T11:14:26.565611 |
Data as of: 2026-03-28 |
Powered by Claude AI